{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:39:17Z","timestamp":1787614757755,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","issue":"3-4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013367","name":"Universidad Tecnol\u00f3gica de Pereira","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Diseases"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.vasdi.2025.05.001","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T07:24:01Z","timestamp":1748503441000},"page":"99-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sociodemographic and pharmacological characteristics of patients with primary and secondary Raynaud's phenomenon. A cross-sectional study"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4245-0101","authenticated-orcid":false,"given":"Luis Fernando","family":"Valladales-Restrepo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Henao-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Velasquez-Quimara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n","family":"Giraldo-Galeano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina Mar\u00eda","family":"Saldarriaga-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8455-0936","authenticated-orcid":false,"given":"Jorge Enrique","family":"Machado-Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vasdi.2025.05.001_bib0130","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jaad.2022.06.1199","article-title":"Epidemiology, pathophysiology, and clinical considerations of primary and secondary Raynaud's phenomenon","volume":"90","author":"Curtiss","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.vasdi.2025.05.001_bib0135","doi-asserted-by":"crossref","first-page":"101474","DOI":"10.1016\/j.berh.2019.101474","article-title":"Raynaud's phenomenon","volume":"34","author":"Herrick","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.vasdi.2025.05.001_bib0140","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/BOR.0000000000000877","article-title":"Practical management of Raynaud's phenomenon\u00a0\u2013\u00a0a primer for practicing physicians","volume":"34","author":"Ramahi","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.vasdi.2025.05.001_bib0145","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1024\/0301-1526\/a000661","article-title":"ESVM guidelines\u00a0\u2013\u00a0the diagnosis and management of Raynaud's phenomenon","volume":"46","author":"Belch","year":"2017","journal-title":"Vasa"},{"key":"10.1016\/j.vasdi.2025.05.001_bib0150","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMra1507638","article-title":"Raynaud's phenomenon","volume":"375","author":"Wigley","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vasdi.2025.05.001_bib0155","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jaad.2022.05.067","article-title":"Part II: the treatment of primary and secondary Raynaud's phenomenon","volume":"90","author":"Curtiss","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.vasdi.2025.05.001_bib0160","doi-asserted-by":"crossref","first-page":"152521","DOI":"10.1016\/j.semarthrit.2024.152521","article-title":"Clinically relevant differences between primary Raynaud's phenomenon and secondary to connective tissue disease","volume":"68","author":"Di Donato","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.vasdi.2025.05.001_bib0165","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00296-018-4133-y","article-title":"Raynaud's phenomenon in Northern Sweden: a population-based nested case-control study","volume":"39","author":"Stjernbrandt","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.vasdi.2025.05.001_bib0170","series-title":"Cobertura de medicamentos","author":"P\u00f3puli","year":"2024"},{"key":"10.1016\/j.vasdi.2025.05.001_bib0175","doi-asserted-by":"crossref","first-page":"e00661","DOI":"10.1002\/prp2.661","article-title":"Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: a systematic review","volume":"8","author":"Franco","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.vasdi.2025.05.001_bib0180","unstructured":"World Health Organization. Promoting rational use of medicines. Available on: https:\/\/www.who.int\/activities\/promoting-rational-use-of-medicines [Accessed May 9, 2024]."},{"key":"10.1016\/j.vasdi.2025.05.001_bib0185","unstructured":"Consulta de datos de productos [Internet]. Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA). Available on: http:\/\/consultaregistro.invima.gov.co\/Consultas\/consultas\/consreg_encabcum.jsp [Accessed September 6, 2024]."},{"key":"10.1016\/j.vasdi.2025.05.001_bib0190","series-title":"Drug Point Summary [database on the Internet]","year":"2025"},{"key":"10.1016\/j.vasdi.2025.05.001_bib0195","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s10654-022-00934-w","article-title":"Biases arising from linked administrative data for epidemiological research: a conceptual framework from registration to analyses","volume":"37","author":"Shaw","year":"2022","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.vasdi.2025.05.001_bib0200","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s10067-021-05598-7","article-title":"How do patients define Raynaud's phenomenon? Differences between primary and secondary disease","volume":"40","author":"Murphy","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.vasdi.2025.05.001_bib0205","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/OARRR.S352655","article-title":"Prevalence of Raynaud's Phenomenon in Saudi Arabia","volume":"14","author":"Mustafa","year":"2022","journal-title":"Open Access Rheumatol"},{"key":"10.1016\/j.vasdi.2025.05.001_bib0210","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/S2665-9913(19)30079-7","article-title":"Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials","volume":"1","author":"Khouri","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.vasdi.2025.05.001_bib0215","doi-asserted-by":"crossref","first-page":"580","DOI":"10.7861\/clinmed.2020-0754","article-title":"Raynaud's phenomenon","volume":"20","author":"Haque","year":"2020","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.vasdi.2025.05.001_bib0220","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1007\/s10067-019-04745-5","article-title":"Raynaud's phenomenon-an update on diagnosis, classification and management","volume":"38","author":"Pauling","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.vasdi.2025.05.001_bib0225","first-page":"29","article-title":"Etiological profile of secondary Raynaud's phenomenon in an internal medicine department. About 121 patients","volume":"43","author":"Ben Salem","year":"2018","journal-title":"J Med Vasc"},{"key":"10.1016\/j.vasdi.2025.05.001_bib0230","first-page":"CD002069","article-title":"Calcium channel blockers for primary Raynaud's phenomenon","volume":"2","author":"Ennis","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vasdi.2025.05.001_bib0235","first-page":"CD000467","article-title":"Calcium channel blockers for primary and secondary Raynaud's phenomenon","volume":"12","author":"Rirash","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vasdi.2025.05.001_bib0240","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/CLEP.S75482","article-title":"Raynaud phenomenon and mortality: 20+ years of follow-up of the Charleston Heart Study cohort","volume":"7","author":"Nietert","year":"2015","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.vasdi.2025.05.001_bib0245","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/03007995.2024.2318058","article-title":"\u03b2-blockers are not all the same: pharmacologic similarities and differences, potential combinations and clinical implications","volume":"40","author":"Taddei","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.vasdi.2025.05.001_bib0250","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","article-title":"Diagnosis and management of migraine in ten steps","volume":"17","author":"Eigenbrodt","year":"2021","journal-title":"Nat Rev Neurol"}],"container-title":["Vascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050658125002031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050658125002031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T11:41:35Z","timestamp":1754566895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050658125002031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":25,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S3050658125002031"],"URL":"https:\/\/doi.org\/10.1016\/j.vasdi.2025.05.001","relation":{},"ISSN":["3050-6581"],"issn-type":[{"value":"3050-6581","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sociodemographic and pharmacological characteristics of patients with primary and secondary Raynaud's phenomenon. A cross-sectional study","name":"articletitle","label":"Article Title"},{"value":"Vascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vasdi.2025.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}